ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1730 • ACR Convergence 2023

    Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients

    Rachel AUDO1, Jérome Thireau2, Louis Rauzier3, Marie Barozet1, JACQUES MOREL4, Patrice Bideaux3, alain Lacampagne2 and Claire Daien5, 1CHU Montpellier, Montpellier, France, 2PhyMedExp INSERM U1046, Montpellier, France, 3PhyMedExp U1046, Montpellier, France, 4Protocole thérapeutique immuno-rhumatologie, Montpellier, France, 5University Hospital, Montpellier, France

    Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
  • Abstract Number: 1625 • ACR Convergence 2023

    Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning

    santiago arciniegas1, Matthias W. Wagner2, Logi Vidarsson2, Birgit Ertl-Wagner2, Tala El Tal3, Asha Jeyanathan2, Lawrence Ng2, Linda Hiraki2, Deborah Levy2, George M. Ibrahim2 and Andrea Knight2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
  • Abstract Number: 1694 • ACR Convergence 2023

    Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE

    Prathyusha Bachali1, Shimon Korish2, Yanhua Hu3, Peter Schafer4, Amrie Grammer1 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2Bristol Myers Squibb, Summit, NJ, 3Bristol Myers Squibb, Princeton, NJ, 4Bristol Myers Squibb, Belle Mead, NJ

    Background/Purpose: Iberdomide is a high affinity cereblon ligand that promotes ubiquitylation and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors and, thereby altering…
  • Abstract Number: 1611 • ACR Convergence 2023

    Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study

    Linoy Israel1, Victoria Furer2, Atan Gross1 and Jacob Ablin2, 1Weizmann Institute of Science, Rehovot, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Fibromyalgia (FM) is among the most common chronic pain conditions, clinically characterized by widespread pain and fatigue. FM pathogenesis remains unknown, leading to challenges…
  • Abstract Number: 1502 • ACR Convergence 2023

    Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study

    Kanako Kojima1, Kunihiro Ichinose1, Toshimasa Shimizu1, Masataka Umeda1, Takahisa Suzuki2, Yoshikazu Nakashima3, Akitomo Okada4, Yoshiro Horai5, Keita Fujikawa6, Toshiyuki Aramaki7, Taiichiro Miyashita8, Masako Furuyama3, Naoki Matsuoka9 and Atsushi Kawakami10, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 3Nagasaki Kita Hospital, Nagasaki, Japan, 4National Hospital Organization Nagasaki Medical Center, Omura, Japan, 5Sasebo City General Hospital, Sasebo, Japan, 6Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, 7Sasebo Chuo Hospital, Sasebo, Japan, 8Miyashita Rheumatology Clinic, Omura, Japan, 9Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, 10Nagasaki University, Nagasaki, Japan

    Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…
  • Abstract Number: 0976 • ACR Convergence 2023

    Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis

    Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN

    Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…
  • Abstract Number: 0968 • ACR Convergence 2023

    Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

    Yumeko Kawano1, Dana Weisenfeld1, Qing Liu1, Mary Jeffway1, Gregory McDermott1, Kumar Dahal1, Jennifer Stuart1, Jacob Joseph2, Tianrun Cai1, Brittany Weber1, Tianxi Cai3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Veteran's Affairs Boston Healthcare System, Boston, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease including heart failure (HF). HF is a heterogeneous condition that is…
  • Abstract Number: 1243 • ACR Convergence 2023

    Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

    Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL

    Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
  • Abstract Number: 1726 • ACR Convergence 2023

    Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis

    Melissa Lim1, Shaghayegh Foroozan2, Zoya Qaiyum3, Michael Tang1, Enoch Yau4 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2University Health Network/University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
  • Abstract Number: 1622 • ACR Convergence 2023

    Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality

    Matthew Sherman1, Payam Noroozi Farhad2, Katherine Pak3, Iago Pinal-Fernandez3, Kakali Sarkar2, Megan Neely4, Ira Targoff5, Frederick Miller6, Andrew Mammen7 and Lisa Rider8, 1NIAMS/NIH, Washington, DC, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, 5Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, 6NIH, NIEHS, Chapel Hill, NC, 7NIH, Bethesda, MD, 8NIEHS, NIH, Bethesda, MD

    Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
  • Abstract Number: 1728 • ACR Convergence 2023

    A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

    Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • Abstract Number: 1631 • ACR Convergence 2023

    Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

    Chloe Peyton1, Tate Johnson1, Joshua Baker2, Yangyuna Yang1, Punyasha Roul1, Michael Duryee1, Jill Poole1, Geoffrey Thiele1, Ted R Mikuls3 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
  • Abstract Number: 1504 • ACR Convergence 2023

    Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S

    Vasileios Kyttaris1, Gelareh Atefi2, Daniel Persons3, Christopher S. Ambrose4, Scott Milligan5 and Sandra Wu6, 1BIDMC, Boston, MA, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 3Trio Health, Denver, CO, 4AstraZeneca, Wilmington, DE, 5Trio Health, Analytics, Louisville, CO, 6AstraZeneca, Hockessin, DE

    Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…
  • Abstract Number: 1254 • ACR Convergence 2023

    Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)

    Amita Aggarwal1, Ranjan Gupta2, Liza Rajasekhar3, Ashish J Mathew4, Parasar Ghosh5, Chengappa Kavadichanda6, Vineeta Shobha7, Bidyut Das8, Manish Rathi9, Avinash Jain10 and Able Lawrence1, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 2All India Institute of Medical Sciences, New Delhi, India, 3Nizam's Institute of Medical Sciences, Madhapur, India, 4Christian Medical College, Vellore, India, 5Govt of West Bengal, Kolkata, India, 6Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 7St. John's National Academy of Health Science, Bangalore, India, 8SCB medical college, Cuttack, India, 9Postgraduate Institute of Medical education and Research, Chandigarh, India, 10SMS Medical College, Lucknow, India

    Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
  • « Previous Page
  • 1
  • …
  • 278
  • 279
  • 280
  • 281
  • 282
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology